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In this study we calculate the effectiveness of pneumococcal conjugate vaccines (PCV)
against invasive pneumococcal disease (IPD) among children under the age of two years
using the indirect cohort method. We also discuss the timeliness of vaccination and the
residual cases of vaccine type IPD.
Methods and Findings
From July 2006 until June 2015, 921 IPD cases were reported and for 618 children (67.1%),
the vaccination status at the time of infection could be accurately determined. Of these, 379
(61.3%) were vaccinated and 239 (38.7%) were not vaccinated. The adjusted vaccine effec-
tiveness (VE) of PCV7 for all included serotypes + 6A was 80% (95% CI: 63–89) for at least
one dose, 97% (89–100) after three primary doses (post primary) and 95% (57–100) post
booster. The adjusted overall VE of PCV13 was 86% (74–93) for at least one dose, 85%
(62–94) post primary and 91% (61–99) post booster. For the additional serotypes included
in PCV13, the adjusted VE was 82% (66–91), 80% (46–93) and 90% (54–98) respectively.
The serotype specific VE for at least one dose was high for serotypes 1 (83%; 15–97), 3
(74%; 2–93), 7F (84%; 18–98) and 19A (77%; 47–90). Only 39.5% of children with IPD
obtained their first dose of PCV7 according to schedule (2nd dose: 32.9%, 3rd dose: 22.0%,
booster dose: 63.6%). For children vaccinated with PCV13 values were slightly better:
43.8%, 33.5%, 26.3% and 74.3% respectively. Among 90 residual cases with PCV7 sero-
types, 73 (81.1%) were in unvaccinated children, and 15 (16.7%) in children who had not
obtained the number of doses recommended for their age, and only two (2.2%) in children
vaccinated according to age. Of 82 cases with PCV13 serotypes occurring after the switch
from PCV7 to PCV13, 56 (68.3%) were not vaccinated, 22 (26.8%) were incompletely vacci-
nated, and four (4.9%) were vaccinated according to age.
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Conclusions
Our data show a high effectiveness of pneumococcal conjugate vaccination in Germany.
However, the administration of vaccine doses among children with IPD is often delayed,
resulting in many vaccine type cases in non- or incompletely-vaccinated children. Whether
the recently-implemented change to a 2+1 schedule will improve the timeliness of vaccina-
tion should be subject to careful monitoring.
Introduction
Streptococcus pneumoniae remains a major cause of infectious disease, especially among the
very young (children<5 years of age) and the elderly (>60 years of age). Apart from causing
diseases like otitis media, pneumonia and meningitis, pneumococci colonize the nasopharynx,
with the highest level of carriage reported from pre-school age children [1, 2]. Pneumococcal
conjugate vaccines have been developed to reduce the burden of disease among children and,
through mucosal immunity, also reduce the carriage of serotypes included in the vaccine.
The first pneumococcal conjugate vaccine, Prevenar (PCV7), comprising the serotypes 4,
6B, 9V, 14, 18C, 19F and 23F, became available in Germany in 2001. Initially, the German
Standing Committee on Vaccination (STIKO) recommended vaccination of children with an
increased risk for pneumococcal disease only. Universal vaccination of all children under two
years of age was recommended in July 2006, with three primary doses at age 2, 3 and 4 months
and a booster at age 11 to 14 months (3 + 1 schedule) [3]. Vaccination was performed with
PCV7 until 2009 when higher valent pneumococcal conjugate vaccines became available. In
April 2009, Synflorix (PCV10), including the PCV7 serotypes plus serotypes 1, 5 and 7F, was
licensed, and in December 2009, Prevenar13 (PCV13), including the PCV10 serotypes plus
serotypes 3, 6A and 19A, replaced PCV7 in Germany. Vaccination costs are fully reimbursed
by the German health insurance companies. The choice of vaccine formulation lies with the
parents and the pediatrician. Currently, the vast majority of children are vaccinated with
PCV13 [4]. The uptake of pneumococcal conjugate vaccine among children under two years of
age in Germany is 80–85% (as based on sold/prescribed doses) [5–8]. In Germany, the intro-
duction of childhood pneumococcal conjugate vaccination has had a profound effect on inva-
sive pneumococcal disease (IPD) and otitis media among children, as well as on the serotype
distribution of IPD among adults [4, 9].
In this study, we calculate the vaccine effectiveness (VE) of PCV7 and PCV13 against IPD
among children under the age of two years using the indirect cohort method described by
Broome [10]. We also report on the timeliness of pneumococcal conjugate vaccination and on
the residual cases with vaccine type IPD.
Materials and Methods
Data collection
Surveillance of IPD among children in Germany has been conducted by the German National
Reference Center for Streptococci (GNRCS) since 1997 and the surveillance system has been
described previously [4]. In this study only cases sent in from July 2006, when childhood pneu-
mococcal conjugate vaccination was recommended, were used. IPD cases were defined as
Streptococcus pneumoniae isolated from blood, cerebrospinal fluid or any other normally sterile
body fluid. A questionnaire requesting data on age, gender, diagnosis and vaccination status
(type of vaccine, vaccination date, batch number) was filled out by the diagnostic laboratories
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and sent in together with the pneumococcal isolates. Incomplete data on vaccination status
were ascertained by contacting the laboratories and treating pediatricians. All data were
entered into the database of the GNRCS in an anonymized way. Cases were grouped per pneu-
mococcal season (from July to June of consecutive years). Since the vaccination status was
ascertained retrospectively, all data were processed to reflect the vaccination status of each
child at the time of infection, i.e. all vaccination doses given after the time of infection were dis-
regarded. To assess the timeliness of pneumococcal conjugate vaccination in Germany, the
actual age at vaccination was compared to the scheduled age (first dose: 60–89 days of age, sec-
ond dose: 90–119 days, third dose: 120–149 days, booster: 330–449 days). The analysis was per-
formed for PCV7 and PCV13.
Characterization of isolates and serotyping
Species identification was performed at the GNRCS using bile and optochin testing. In dubious
cases, PCR analysis of several genes was performed (ply, lytA, sodA, 16S-rRNA). As a last
resort, MLST was performed. Pneumococcal isolates were serotyped by Neufeld’s Quellung
reaction using type and factor sera provided by the Statens Serum Institut, Copenhagen, Den-
mark. Isolates were considered non-typeable when there was no reaction with any of the
antisera.
Calculation of vaccine effectiveness
VE was calculated using the indirect cohort method as described by Broome [10]. In this calcu-
lation, patients with non-vaccine serotype IPD are used as controls for the cases of patients
with vaccine serotype IPD. The assumption is that the risk of developing non-vaccine serotype
disease is independent of the patient’s vaccination status. A comparison of the odds of vaccina-
tion in patients with vaccine type and non-vaccine type disease allows for the calculation of
VE. VE was calculated for children having obtained one or more doses of vaccine (at least one
dose), for children with a completed primary schedule, i.e. three doses and age<449 days at
onset of disease (post primary) and for children with a completed schedule, i.e. four doses (post
booster).
A vaccination dose was only counted when given at least fourteen days before onset of dis-
ease. Children aged<74 days at onset of disease, i.e. too young to be vaccinated, were excluded
from the analysis. The maximum age for inclusion in the study was 729 days at onset of disease.
The following age cohorts were used for VE calculation: children aged 74–729 days were
included in the ‘at least one dose’ analysis, children aged 150-<449 days in the ‘post primary’
cohort and children aged 330–729 days in the ‘post booster’ cohort.
Only children with complete information on vaccination status, i.e. date of vaccination and
type of vaccine, were included in the analysis. To reflect the conjugate vaccine introduction in
Germany, the analysis was split in two periods. From July 2006 until June 2010, children vacci-
nated with PCV7 were analysed. From July 2010 until June 2015, vaccinations with PCV13
were assessed. Due to the very low use of PCV10 in Germany, and the resulting low number of
cases of PCV10-vaccinated children, a calculation of PCV10 VE was not performed.
Statistical analysis
Vaccine effectiveness was calculated using the formula: VE = 1 –odds of being vaccinated in a
vaccine type case / odds of being vaccinated in a non-vaccine type case. Odds ratios (OR) and
95% confidence intervals (CI) were estimated using Firth's bias-reduced logistic regression as
described by Heinze [11]. Confidence intervals that do not cross zero are considered statisti-
cally significant. VE was adjusted for age and season following the issue of the vaccination
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recommendation. All calculations were performed using R (version 3.1.1, The R Foundation
for Statistical Computing, Vienna, Austria).
Ethical statement
An ethical approval was not required since the study was performed with Streptococcus pneu-
moniae isolates that resulted from routine microbiological diagnostic procedures as requested
by the treating physician. No additional biological specimens were taken for the purpose of this
study. Specimens were anonymized and only data on birthdate, sex, type of specimen, vaccina-
tion status and hospital/laboratory where the case was diagnosed were registered.
Results
From July 2006 until June 2015, a total of 921 cases of IPD among children under two years of
age were reported to the GNRCS. Ages varied from 0 to 23 months with 244 (26.5%) children
aged 0–5 months, 282 (30.6%) aged 6–11 months, 249 (27.0%) aged 12–17 months and 146
(15.9%) aged 18–23 months. 552 (59.9%) patients were male, 357 (38.8%) female and for 12
patients gender was not reported.
For 165 (17.9%) children the vaccination status could not be ascertained, for 63 (6.8%) chil-
dren vaccination data were incomplete and 75 (8.1%) children were excluded from the analysis
because they were younger than 74 days. For 618 children (67.1%), the vaccination status at the
time of infection could be accurately determined. Of these, 379 (61.3%) were vaccinated and
239 (38.7%) were not vaccinated. Among the vaccinated children, 125 (33.0%) were vaccinated
with PCV7, 32 (8.4%) with PCV10 and 221 (58.3%) were vaccinated with PCV13 at the time of
infection. One child had received a primary series of PCV10 and a booster with PCV13 and
this case was excluded from further analysis. The percentage of children vaccinated with at
least one dose of any PCV at the time of infection gradually increased from 25.6% in 2006–
2007 to 83.8% in 2014–2015 (Fig 1).
Serotype distribution varied over time as a result of the vaccination with pneumococcal con-
jugate vaccines. Both during the PCV7 period as well as during the PCV13 period the number
of IPD cases caused by serotypes included in the respective vaccines decreased every year. [4]
Fig 1. Vaccination status at time of infection of 618 children with IPD reported to the GNRCS from July 2006
–June 2015.Red: not vaccinated, dark blue: vaccinated with PCV7, light blue: vaccinated with PCV10, blue:
vaccinated with PCV13. The black line represents the percentage of children vaccinated at the time of infection
among the cases for which the vaccination status could be ascertained. Left Y-axis: number of cases, right y-axis:
percentage of vaccinated children.
doi:10.1371/journal.pone.0161257.g001
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Vaccine effectiveness
For the analysis of PCV7 vaccine effectiveness, 255 IPD cases fulfilling the above described cri-
teria (age 74–729 days, case between July 2006 and June 2010) were included. Ten cases vacci-
nated with PCV10 and two cases vaccinated with PCV13 (most of them reported in 2009–
2010) were excluded (Fig 1). The adjusted VE for all PCV7 serotypes including 6A was 80% for
at least one dose, 97% post primary and 95% post booster (Table 1). The adjusted VE for single
serotypes included in PCV7 in the ‘at least one dose’ cohort varied from 8% for serotype 18C to
90% for serotypes 6B and 14, for post primary VEs varied from 51% for serotype 4 to 97% for
serotype 6B and 14, for post booster most VE values were lower and with wide CIs crossing
zero, due to low numbers of both vaccinated and unvaccinated cases. For serotype 6A, adjusted
VEs of 73% for at least one dose, 91% post primary and 74% post booster were calculated
which is consistent with cross-protection of serotype 6B antibodies induced by PCV7 towards
this serotype. However, the VE values had wide CIs, and the cohort sizes of the latter two age
groups had very low numbers.
The VE for PCV13 was calculated for the period July 2010 till June 2015 and included 317
cases (age 74–729 days, and excluding 11 cases vaccinated with PCV7 and 22 cases vaccinated
with PCV10 and most of them reported in 2010–2011 (Fig 1). For all PCV13 serotypes, the
adjusted VE was 86% for at least one dose, 85% post primary and 91% post booster (Table 2).
For the six serotypes unique to PCV13 (PCV13-non-PCV7 serotypes), adjusted VE values
were 82%, 80% and 90% respectively. For the 7 serotypes present in both PCV7 and PCV13,
adjusted VEs were 94%, 99% and 83% respectively. Serotype specific VE was high for serotypes
1, 6A, 7F and 19A. Serotype 5 cases are very rare in Germany and did not occur in the PCV13
analysis period. For serotype 3, the VE for ‘at least one dose’ was 74%. VEs for ‘post primary’
and ‘post booster’ were 80% and 63% respectively, however, with wide 95% CIs and lower lim-
its below zero and very small cohort sizes.
Timeliness of vaccination
Among 114 children vaccinated with a first dose of PCV7 between July 2006 and June 2010, 45
(39.5%) had received this dose according to schedule (in the 3rd month of life). Among 82 chil-
dren vaccinated with a second dose, 27 (32.9%) had obtained their second dose in time, 13 of
59 children (22.0%) were vaccinated with a third dose according to schedule. Seven of 11 chil-
dren (63.6%) had obtained their booster dose according to schedule (Fig 2). For children vacci-
nated with PCV13 between July 2010 and June 2015, proportions were somewhat higher:
43.8% (96/219), 33.5% (64/191), 26.3% (40/152) and 74.3% (26/35) respectively (Fig 3).
In the PCV7 period (July 2006 until June 2010), a total of 90 IPD cases caused by a serotype
included in the vaccine occurred (Table 3). Of these, 73 (81.1%) were in unvaccinated children,
and 15 (16.7%) in children that were incompletely vaccinated, i.e. that had not obtained the
number of doses recommended for their age. Only two cases (2.2%) with PCV7 serotypes
occurred in children vaccinated according to schedule.
In the PCV13 vaccination period (July 2010 until June 2015), 82 IPD cases due to a vaccine
serotype occurred (Table 3). Among these 56 (68.3%) were not vaccinated, 22 (26.8%) were
incompletely vaccinated, and four (4.9%) were vaccinated according to age. As described
above, 33 cases vaccinated with PCV7 and PCV10 were excluded from the PCV13 period (Fig
1). Interestingly, among these 33, another 11 cases with PCV13 serotypes were reported
(Table 3).
In Table 4 we have listed the residual vaccine serotype cases that occurred in vaccinated
children. Both in the PCV7 period (2006–2010) as well as in the higher-valent vaccination
period (2010–2015), the number of vaccine type cases decreased continuously. Most cases in
PCV Vaccine Effectiveness in German Children
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PCV7 serotypes + 6A*
at least one
dose
20:81 94:60 84% (72 to 91) 80% (63 to 89)
post primary 1:49 38:27 98% (91 to 100) 97% (89 to 100)




0:1 94:60 79% (-307 to 100) 70% (-636 to 100)
post primary 0:1 38:27 76% (-364 to 100) 51% (-1088 to 100)




2:20 94:60 92% (74 to 98) 90% (66 to 98)
post primary 0:15 38:27 98% (82 to 100) 97% (72 to 100)




0:4 94:60 93% (32 to 100) 89% (-13 to 100)
post primary 0:2 38:27 86% (-85 to 100) 83% (-158 to 100)




2:24 94:60 93% (79 to 99) 90% (68 to 98)
post primary 0:12 38:27 97% (77 to 100) 97% (71 to 100)




4:6 94:60 56% (-52 to 88) 8% (-239 to 76)
post primary 0:3 38:27 90% (-11 to 100) 79% (-137 to 100)




5:11 94:60 69% (14 to 90) 55% (-34 to 87)
post primary 1:6 38:27 84% (15 to 98) 73% (-44 to 97)




3:8 94:60 74% (11 to 94) 61% (-62 to 92)
post primary 0:6 38:27 95% (50 to 100) 89% (-23 to 100)




4:7 94:60 62% (-26 to 90) 73% (1 to 93)
post primary 0:4 38:27 92% (21 to 100) 91% (8 to 100)
post booster 0:1 11:19 43% (-1054 to 100) 74% (-478 to 100)
* Serotype 6A is not included in PCV7, but antibodies against serotype 6B are crossprotective towards 6A.
¶This value can not be strictly interpreted due to insufficient number of events
doi:10.1371/journal.pone.0161257.t001
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the higher-valent vaccination period were serotype 19A (n = 23) but only three of these chil-
dren were vaccinated according to schedule, and only one of those had obtained a full vaccina-
tion schedule of four doses.















25:55 194:43 90% (82 to 94) 86% (74 to 93)
post primary 10:22 74:20 87% (70 to 95) 85% (62 to 94)




23:43 194:43 88% (78 to 93) 82% (66 to 91)
post primary 10:16 74:20 82% (57 to 93) 80% (46 to 93)
post booster 2:12 33:16 90% (62 to 98) 90% (54 to 98)
PCV7 serotypes in PCV13
at least one
dose
2:12 194:43 96% (84 to 99) 94% (78 to 99)
post primary 0:6 74:20 98% (81 to 100) 99% (80 to 100)




2:5 194:43 90% (56 to 98) 83% (15 to 97)
post primary 1:2 74:20 84% (-31 to 99) 49% (-614 to 96)




6:5 194:43 74% (10 to 92) 74% (2 to 93)
post primary 1:2 74:20 84% (-31 to 99) 80% (-68 to 98)





post primary 0:0 74:20




0:4 194:43 95% (55 to 100) 96% (56 to 100)
post primary 0:1 74:20 91% (-78 to 100) 84% (-214 to 100)




1:12 194:43 97% (88 to 100) 84% (18 to 98)
post primary 0:2 74:20 95% (29 to 100) 86% (-116 to 100)




14:17 194:43 81% (60 to 92) 77% (47 to 90)
post primary 8:9 74:20 75% (30 to 92) 73% (18 to 92)
post booster 1:7 33:16 90% (49 to 99) 88% (25 to 99)
doi:10.1371/journal.pone.0161257.t002
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Fig 2. Timeliness of pneumococcal conjugate vaccination (PCV7) of children under two years of age with
IPD in Germany (July 2006 –June 2010). Bars indicate scheduled vaccination times, lines indicate cumulative
actual vaccination rates in percentage (red: 1st dose, orange: 2nd dose, yellow: 3rd dose, green: booster dose). Only
doses given before the time of infection were taken into consideration.
doi:10.1371/journal.pone.0161257.g002
Fig 3. Timeliness of pneumococcal conjugate vaccination (PCV13) of children under two years of age with
IPD in Germany (July 2010 –June 2015). Bars indicate scheduled vaccination times, lines indicate cumulative
actual vaccination rates in percentage (red: 1st dose, orange: 2nd dose, yellow: 3rd dose, green: booster dose). Only
doses given before the time of infection were taken into consideration.
doi:10.1371/journal.pone.0161257.g003
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Discussion
The vaccination data of 618 IPD cases among children under 2 years of age were available for
our VE calculations. Our data show high VEs for both PCV7 and PCV13, which is in accor-
dance with our data published on the changes in serotype distribution among both children
and adults [4]. Adjusting for age and season following the issue of the vaccination recommen-
dation resulted in slightly lower VE values in comparison to the crude values for most PCVs
and single serotypes. Due to the quick disappearance of vaccine serotypes after start of vaccina-
tion, many VE estimates for single serotypes did not reach statistical significance.
Table 3. IPD cases among children under two years of age caused by serotypes included in PCV7 (2006–2010, among 141 non-vaccinated and 114
PCV7 vaccinated cases (A)) and PCV13 (2010–2015, among 98 non-vaccinated cases, 317 PCV13 vaccinated cases (B) and 11 PCV7 and 22 PCV10
vaccinated cases (C)).
season vaccination status 4 6B 9V 14 18C 19F 23F 1 3 5 6A 7F 19A total
A 2006–2007 not vaccinated 1 11 2 13 3 5 7 42
incomplete (PCV7) 1 2 2 2 1 8
according to age (PCV7) 1 1
2007–2008 not vaccinated 7 2 5 1 2 17
incomplete (PCV7) 1 1 1 1 2 6
according to age (PCV7) 1 1
2008–2009 not vaccinated 1 4 1 6
incomplete (PCV7) 0
according to age (PCV7) 0
2009–2010 not vaccinated 1 1 2 4 8
incomplete (PCV7) 1 1
according to age (PCV7) 0
2006–2010 all 1 22 4 26 10 16 11 90
B 2010–2011 not vaccinated 1 1 3 2 1 8 8 24
incomplete (PCV13) 2 1 3 6
2011–2012 not vaccinated 1 1 2 4 4 1 13
incomplete (PCV13) 1 1 3 5
according to age (PCV13) 1 1 2
2012–2013 not vaccinated 2 1 1 2 6
incomplete (PCV13) 1 2 4 7
according to age (PCV13) 1 1
2013–2014 not vaccinated 1 1 1 1 3 7
incomplete (PCV13) 1 1 1 3
2014–2015 not vaccinated 2 1 1 2 6
incomplete (PCV13) 1 1
according to age (PCV13) 1 1
2010–2015 all 4 2 1 7 7 11 4 15 31 82
C 2010–2011 incomplete (PCV7) 2 2
incomplete (PCV10) 3 3
according to age (PCV7) 2 2
according to age (PCV10) 1 1
2011–2012 incomplete (PCV10) 1 1
according to age (PCV10) 1 1
2012–2013 incomplete (PCV10) 1 1
2010–2015 all 1 1 1 8 11
doi:10.1371/journal.pone.0161257.t003
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Table 4. IPD cases among vaccinated children with PCV7 serotypes (2006–2010) and PCV13 serotypes (2010–2015).
Season Diagnosis Age
(months)
Serotype Vaccine Vaccination status at infection
2006–
2007
meningitis 10 6B PCV7 no 2nd, no 3rd dose
meningitis 4 14 PCV7 no 2nd dose
3 14 PCV7 no 2nd dose
meningitis 3 18C PCV7 according to schedule, 2 doses, infection four days after
2nd dose
4 18C PCV7 no 2nd dose
septic arthritis 4 18C PCV7 no 2nd dose
meningitis 12 19F PCV7 no 2nd, no 3rd, no booster dose
5 19F PCV7 no 2nd dose
meningitis 6 23F PCV7 no 2nd, no 3rd dose
2007–
2008
sepsis 3 6B PCV7 no 2nd dose
4 14 PCV7 no 2nd dose
sepsis 3 18C PCV7 no 2nd dose
9 19F PCV7 according to schedule, 3 doses, infection at 286 days (9,5
months)
meningitis 13 19F PCV7 no 3rd, no booster dose
5 23F PCV7 no 2nd dose
meningitis 8 23F PCV7 no 2nd, no 3rd dose
2009–
2010
sepsis, otitis media 23 19F PCV7 no booster dose
2010–
2011
pneumonia 15 1 PCV13 no booster dose
pneumonia 14 1 PCV13 no booster dose
pneumonia 15 3 PCV13 no booster dose
meningitis 12 6B PCV10 according to schedule, 4 doses
22 19A PCV7 according to schedule, 4 doses
otitis media, pharyngitis 10 19A PCV10 no 3rd, no booster dose
14 19A PCV7 according to schedule, 4 doses
pneumonia, sepsis, otitis media,
mastoiditis
12 19A PCV7 no booster dose
phlegmon 15 19A PCV13 no booster dose
meningitis 17 19A PCV10 no booster dose
pneumonia 16 19A PCV10 no booster dose
pneumonia 20 19A PCV7 no booster dose
meningitis 11 19A PCV13 no booster dose
mastoiditis 11 19A PCV13 no booster dose
2011–
2012
pneumonia, pleuraempyema 15 3 PCV13 according to schedule, 4 doses
pneumonia 15 3 PCV13 no 3rd, no booster dose
meningitis, sepsis 5 7F PCV13 no 3rd dose
sepsis 18 14 PCV10 no booster dose
sepsis 13 19A PCV13 no booster dose
sepsis, pneumonia, pleuraempyema 10 19A PCV13 no booster dose
mastoiditis 21 19A PCV13 according to schedule, 4 doses
mastoiditis 18 19A PCV13 no booster dose
mastoiditis 20 19F PCV10 according to schedule, 4 doses
(Continued)
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The VE for PCV7 was high, reaching 97% after three doses, leading to a complete disappear-
ance of vaccine type cases among vaccinated individuals who had received the full 3+1 schedule
including the booster dose. Our VE estimate of 80% (95% CI: 63–89) for at least one dose was
comparable to 79% (95% CI: 84–93) found in England and Wales [12], 90% (82–95) in Quebec
[13], 88% (78–94) in the U.S.A. [14] and 91.3% (46.4–98.6) in Uruguay [15]. This shows little
difference in effectiveness of a 3+1 schedule (Germany, USA) as compared to a 2+1 schedule
(England and Wales, Quebec, Uruguay).
For the single serotypes, most VE values were comparable to those found in England and
Wales [12]. For serotype 18C VE for at least one dose could not be demonstrated (8%; 95% CI:
-239-76). This is in contrast with the adjusted value of 94% (95% CI: 64–99) found in England
andWales. However, the decrease from the unadjusted value of 56% was strongly driven by the
fact that no 18C cases were received in the third post-PCV7 season (2008–2009). For compari-
son, 18C comprised 16.6% of isolates in 2006–2007, 5.4% in 2007–2008, and 4.8% of the iso-
lates in 2009–2010. Also, due to the small number of cases, the CI of our VE estimate was very
wide. None of the post booster VEs for single serotypes reached significance, because of the
low number of cases. Our data suggest cross-protection towards serotype 6A, even though the
VE values do not reach statistical significance.
The VE for PCV13 was high, reaching 91% (95% CI: 61–99) for all serotypes and 90% (54–
98) for the six additional serotypes, post booster. The values of 75% (95% CI: 58–84; at least
two doses before age 12 months or one dose on or after 12 months) and 79% (25–94) reported
for a 2+1 dosing schedule in England, Wales and Northern Ireland, show similar effectiveness,
with lower point estimates, but widely overlapping confidence intervals [16]. Harboe et al.
report an 85% incidence reduction for the additional serotypes in PCV13 when comparing the
PCV7 vaccination period with the PCV13 vaccination period [17] and Moore et al. report an
incidence difference of 93% (91–94) between expected and actual case counts among children
under 5 years of age in the USA, three years after the introduction of PCV13 [18].
Our data show effectiveness for at least one dose for serotypes 1 (83%; 95% CI: 15–97), 6A
(96%; 56–100), 7F (84%; 18–98) and 19A (77%; 47–90), which is very similar to the effective-
ness reported from England, Wales and Northern Ireland (84%; 54–95, 96%; 41–100, 91%; 70–




Serotype Vaccine Vaccination status at infection
2012–
2013
sepsis 10 3 PCV13 no booster dose
HUS 19 3 PCV13 no booster dose
meningitis, mastoiditis 13 19A PCV13 no booster dose
pneumonia, sepsis 3 19A PCV13 according to schedule, 1 dose
invasive myositis 14 19A PCV10 no 3rd, no booster dose
meningitis 4 19A PCV13 no 2nd dose
pneumonia 13 19A PCV13 no booster dose
5 19A PCV13 no 2nd dose
otitis media, mastoiditis 7 19F PCV13 no 3rd dose
2013–
2014
mastoiditis 17 3 PCV13 no booster dose
14 19A PCV13 no booster dose
mastoiditis 10 19F PCV13 no 2nd, no 3rd dose
2014–
2015
pneumonia 22 19A PCV13 no 3rd, no booster dose
meningitis, sepsis 3 19A PCV13 according to schedule, IPD 10 days after first dose
doi:10.1371/journal.pone.0161257.t004
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shows an effectiveness of PCV13 for serotype 3 (74%; 95% CI: 2–93) for at least one dose of
vaccine. This is in contrast to the VE (66%; 95% CI: -322-92) for two doses before age 12
months reported from England, Wales and Northern Ireland, and the VE (39%; 95% CI: -92-
77) reported from Denmark where the point estimates are positive but the CIs are wide and
include zero. The post primary and post booster point estimate VEs for serotype 3 in Germany
are 80% (95% CI: -68-98) and 63% (95% CI: -393-97) respectively, but have CIs including zero,
likely due to small cohort sizes. For the seven serotypes common to PCV7 and PCV13, a VE of
94% (95% CI: 78–99) for at least one dose was found, which is similar to the 80% (95% CI: 63–
89) found for at least one dose of PCV7 and shows the high effectiveness of PCV13 towards
these serotypes.
Our data on the timeliness of pneumococcal conjugate vaccination among children with
IPD show a considerable delay in the administration of the doses. One fifth of the children had
not had a single dose of PCV7 at age 4 months, for PCV13 this was 11%. And only 22.0%
(PCV7) and 26.3% (PCV13) of children finished their primary schedule in time. Booster doses
are also delayed, with only two thirds (PCV7) and three quarters (PCV13) of the children
being boostered within the scheduled time. It should be noted that we only analysed data from
children with IPD and that these children may not be representative for all children in Ger-
many. Interestingly enough, when we calculated the timeliness of vaccination using only non-
vaccine type IPD, the values were only marginally different (0–1%). Furthermore, the Robert
Koch Institute has published data on the timeliness of pneumococcal vaccination among
healthy children showing a very similar delay in administration of the doses, with only 40–50%
of children having a had their third dose at age of 6 months and only 30–40% having had a
booster dose at age 15 months [19]. The delays in administration of PCVs in Germany may in
part be due to the fact that STIKO only issues recommendations, but vaccinations are given by
pediatricians working in their own practices and there is no incentive for either parents or
pediatricians to adhere to the recommended schedules. The delay results in many children hav-
ing insufficient protection, and may have been one of the reasons the children in our cohort
got IPD. A vaccination uptake of>90% is only reached with a 3–5 month delay for the primary
doses, and not until the age of 17 months have all children received a complete 3+1 schedule.
In this light, the recent change (August 2015) of the STIKO recommendation from a 3+1 to a 2
+1 schedule, leaving out the second dose at 3 months of age [19, 20], has to be critically
assessed. Data from England,Wales and Northern Ireland, Norway and Denmark show the
high effectiveness of 2+1 schedules. However, vaccination uptake in these countries exceeds
90% [17, 21, 22] and in England there are incentives for practicioners encouraging strict adher-
ence to vaccination schedules [23, 24]. If the 2+1 schedule is implemented in Germany with
similarly poor adherence, this may result in a diminished level of individual as well as herd
protection.
Exemplifying the lack of protection due to delayed administration are the vaccine type cases
reported during the PCV7 and PCV13 vaccination periods. Of all cases with a PCV7 serotype,
81.1% were not vaccinated and 16.7% were incompletely vaccinated, and for a large part this
was due to a delayed administration of primary doses. There were no specific predominant vac-
cine serotypes in these incompletely vaccinated cases, however, the only three cases with three
primary doses but lacking the booster dose were all 19F. We have reported on a case of 19F
IPD in a non-boostered child before [25] and it seems that 19F is persisting in the community
longer than other vaccine serotypes as published recently by our group [4].
In the PCV13 period, 26.8% (n = 22) of IPD cases with a PCV13 serotype occurred in chil-
dren incompletely vaccinated with PCV13. Seventeen cases lacked a booster dose and ten of
them were serotype 19A. Another five cases with serotype 19A were found among children
vaccinated with PCV10 and lacking a booster dose. This once more shows the importance of
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the booster dose, but also the persisting circulation of serotype 19A among children in the
PCV13 vaccination period, similar to the persistence of serotype 19F in the PCV7 period [4].
Our study has several limitations. Aside from systemic immunity, pneumococcal conjugate
vaccines also illicit mucosal immunity. Therefore, they reduce the carriage of vaccine serotypes
in immunized children, and thus reduce the circulation of vaccine serotypes among children.
This means that even non-vaccinated children have a lower chance of carrying and getting
infected with vaccine serotypes (herd protection), albeit with a temporal delay compared to the
vaccinated children. Andrews et al. [12, 16] have assessed this bias by correcting for the differ-
ence in probability of non-vaccine type carriage in both vaccinated and unvaccinated individu-
als. Since data on carriage are not available for Germany, we could not use this correction
method and our vaccine effectiveness data are likely to be slightly overestimated. Adjusting our
data with the carriage parameters used by Andrews et al. showed an overestimation of 0.5–5%
for most VE values. Furthermore, our data were not adjusted for underlying disease or other
risk factors, because these data were not available as IPD is not a notifiable disease in Germany,
and as such pertinent information on our case report forms was limited. Another limitation to
our study, and indeed in many other published studies using logistic regression to estimate
odds ratios for VE calculations, is that low event numbers (at least 5–10 events per predictor
variable are recommended [26, 27]), which commonly occur in the rapidly-disappearing vac-
cine-type serotypes, strongly contribute to instability in the results of the regression models,
and thus the VE calculations of these small cohorts should not be strictly interpreted, as values
could be misleading. This is particularly evident in the PCV7 post booster VEs for serotypes 4
and 9V, where case numbers are so low that adjustment results in negative point estimates and
extremely wide CIs.
Conclusions
Our data show a high vaccine effectiveness for both 7- and 13-valent conjugate vaccines used
in Germany administered in a 3+1 schedule. For the individual serotypes, the calculated effec-
tiveness was high both for the serotypes common to PCV7 and PCV13 as well as for the addi-
tional serotypes in PCV13, including serotype 3. Most vaccine type IPD cases occurred in
unvaccinated or only partially vaccinated children. Better adherence to the recommended vac-
cination schedule could have prevented most of these cases. Careful monitoring of the effects
of the recent change from a 3+1 schedule to a 2+1 schedule on the incidence of vaccine type
pneumococcal disease in Germany is necessary.
Acknowledgments
We thank all German microbiological diagnostic laboratories for sending isolates to the Ger-
man National Reference Center.
Author Contributions
Conceptualization:MLMI.
Formal analysis:ML SP CF MI.
Funding acquisition:ML.
Investigation:ML GF SP CF MI.
Methodology:ML GF SP CF MI.
Project administration:ML.
PCV Vaccine Effectiveness in German Children
PLOS ONE | DOI:10.1371/journal.pone.0161257 August 15, 2016 13 / 15
Supervision:ML.
Validation:ML GF SP CF MI.
Visualization:ML.
Writing - original draft:ML.
Writing - review & editing:ML GF SP CF MI.
References
1. Camilli R, Daprai L, Cavrini F, Lombardo D, D'Ambrosio F, Del Grosso M, et al. Pneumococcal carriage
in young children one year after introduction of the 13-valent conjugate vaccine in Italy. PLoS One.
2013; 8(10):e76309. doi: 10.1371/journal.pone.0076309 PMID: 24124543; PubMed Central PMCID:
PMC3790677.
2. Hussain M, Melegaro A, Pebody RG, George R, EdmundsWJ, Talukdar R, et al. A longitudinal house-
hold study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect.
2005; 133(5):891–8. Epub 2005/09/27. doi: S0950268805004012 [pii] doi: 10.1017/
S0950268805004012 PMID: 16181510.
3. Ständige Impfkommission (STIKO). Empfehlungen der Ständigen Impfkommission (STIKO) am RKI
(Stand Juli 2006):Begründungen zur allgemeinen Empfehlung der Impfung gegen Pneumokokken-
und Meningokokken im Säuglings- und Kindesalter. Epidemiol Bull. 2006;(31: ):255–60.
4. van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M. Effects of Infant Pneumococcal Conjugate
Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in
Germany. PLoS One. 2015; 10(7):e0131494. doi: 10.1371/journal.pone.0131494 PMID: 26132078;
PubMed Central PMCID: PMC4488910.
5. Rückinger S, van der Linden M, Reinert RR, von Kries R, Burckhardt F, Siedler A. Reduction in the inci-
dence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conju-
gate vaccine in Germany. Vaccine. 2009; 27(31):4136–41. Epub 2009/05/02. doi: S0264-410X(09)
00611-2 [pii] doi: 10.1016/j.vaccine.2009.04.057 PMID: 19406190.
6. Rückinger S, van der Linden M, Reinert RR, von Kries R. Efficacy of 7-valent pneumococcal conjugate
vaccination in Germany: An analysis using the indirect cohort method. Vaccine. 2010. Epub 2010/06/
16. doi: S0264-410X(10)00697-3 [pii] doi: 10.1016/j.vaccine.2010.05.021 PMID: 20546832.
7. Weiss S, Falkenhorst G, van der Linden M, Imöhl M, von Kries R. Impact of 10- and 13-valent pneumo-
coccal conjugate vaccines on incidence of invasive pneumococcal disease in children aged under 16
years in Germany, 2009 to 2012. Euro Surveill. 2015; 20(10):21057.PMID: 25788255.
8. Theidel U, Braem A, Ruckinger S. [Determination of vaccination quotas for pneumococcal conjugate
vaccine in children on the basis of routine data of the statutory health insurance]. Gesundheitswesen.
2013; 75(5):309–16. doi: 10.1055/s-0032-1321747 PMID: 23073984.
9. van der Linden M, Imöhl M, Busse A, Rose M, Adam D. Bacterial spectrum of spontaneously ruptured
otitis media in the era of pneumococcal conjugate vaccination in Germany. Eur J Pediatr. 2015; 174
(3):355–64. doi: 10.1007/s00431-014-2409-0 PMID: 25169065.
10. Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination: an
alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med. 1980; 303
(10):549–52. Epub 1980/09/04. doi: 10.1056/NEJM198009043031003 PMID: 6995835.
11. Heinze G. A comparative investigation of methods for logistic regression with separated or nearly sepa-
rated data. Stat Med. 2006; 25(24):4216–26. doi: 10.1002/sim.2687 PMID: 16955543.
12. Andrews N, Waight PA, Borrow R, Ladhani S, George RC, Slack MP, et al. Using the indirect cohort
design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England
and wales. PLoS One. 2011; 6(12):e28435. Epub 2011/12/14. doi: 10.1371/journal.pone.0028435
PONE-D-11-17839 [pii].PMID: 22164292.
13. Deceuninck G, De Serres G, Boulianne N, Lefebvre B, DeWals P. Effectiveness of three pneumococ-
cal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;
33(23):2684–9. doi: 10.1016/j.vaccine.2015.04.005 PMID: 25887086.
14. De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, Petit S, et al. Use of surveillance data
to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5
years of age over a 9 year period. Vaccine. 2012; 30(27):4067–72. doi: 10.1016/j.vaccine.2012.04.017
PMID: 22525797.
15. Picon T, Alonso L, Garcia Gabarrot G, Speranza N, Casas M, Arrieta F, et al. Effectiveness of the 7-
valent pneumococcal conjugate vaccine against vaccine-type invasive disease among children in
PCV Vaccine Effectiveness in German Children
PLOS ONE | DOI:10.1371/journal.pone.0161257 August 15, 2016 14 / 15
Uruguay: an evaluation using existing data. Vaccine. 2013; 31 Suppl 3:C109–13. doi: 10.1016/j.
vaccine.2013.01.059 PMID: 23777683.
16. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effective-
ness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure
indirect cohort study. Lancet Infect Dis. 2014; 14(9):839–46. doi: 10.1016/S1473-3099(14)70822-9
PMID: 25042756.
17. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molbak K, Slotved HC, et al. Impact of 13-valent
pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin
Infect Dis. 2014; 59(8):1066–73. doi: 10.1093/cid/ciu524 PMID: 25034421.
18. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-
valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and
adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015; 15
(3):301–9. doi: 10.1016/S1473-3099(14)71081-3 PMID: 25656600.
19. Ständige Impfkommission (STIKO). Wissenschaftliche Begründung zur Änderung der Pneumokokken-
Impfempfehlung für Säuglinge. Epidemiol Bull. 2015;(36: ):377–92.
20. Ständige Impfkommission (STIKO). Empfehlungen der Ständigen Impfkommission (STIKO) am Robert
Koch-Institut/Stand: August 2015. Epidemiol Bull. 2015;(34: ):339–40.
21. Steens A, Bergsaker MA, Aaberge IS, Ronning K, Vestrheim DF. Prompt effect of replacing the 7-valent
pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumo-
coccal disease in Norway. Vaccine. 2013; 31(52):6232–8. doi: 10.1016/j.vaccine.2013.10.032 PMID:
24176490.
22. Screening and Immunisations team, Centre HaSCI. NHS Immunisation Statistics 2014 [Feb 4, 2016].
Available from: http://www.hscic.gov.uk/catalogue/PUB14949/nhs-immu-stat-eng-2013-14-rep.pdf.
23. Schmitt HJ, Booy R, Weil-Olivier C, Van Damme P, Cohen R, Peltola H. Child vaccination policies in
Europe: a report from the Summits of Independent European Vaccination Experts. Lancet Infect Dis.
2003; 3(2):103–8.PMID: 12560196.
24. England NHS. General Medical Services Statement of Financial Entitlements Directions 2013 2013
[Feb 4, 2016]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_
data/file/233366/gen_med_servs_statement_financial_entitlements_directions_2013_acc.pdf.
25. KunzeW, van der Linden M, Klemm T, Gröger K. Meningitis durch Streptococcus pneumoniae Serotyp
19F. Pädiatr Praxis. 75. München: Hans Marseille Verlag GmbHMünchen; 2010. p. 249–54.
26. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events
per variable in logistic regression analysis. J Clin Epidemiol. 1996; 49(12):1373–9.PMID: 8970487.
27. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression.
Am J Epidemiol. 2007; 165(6):710–8. doi: 10.1093/aje/kwk052 PMID: 17182981.
PCV Vaccine Effectiveness in German Children
PLOS ONE | DOI:10.1371/journal.pone.0161257 August 15, 2016 15 / 15
